1. Immune modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinically approved response modifiers improves clinical status, blood cell regeneration and gives rise to leukemia specific adaptive and innate immune reactive cells. (March 2018) Authors: Schmid, C.; Atzler, M.; Rank, A.; Inngjerdingen, M.; Rabe, A.; Deen, D.; Wang, R.; Eiz-Vesper, B.; Schmetzer, H. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers. (March 2019) Authors: Atzler, M.; Rank, A.; Inngjerdingen, M.; Rabe, A.; Deen, D.; Wang, R.; Eiz-Vesper, B.; Schmid, C.; Schmetzer, H. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P475: CONTROL LEUKEMIA BY INDUCING ANTI-CANCER IMMUNE REACTIVITY IN VIVO? POTENTIAL OF A DC-TRIGGERED MECHANISM. (23rd June 2022) Authors: Filippini Velazquez, G.; Amberger, D.; Klauer, L.; Rackel, E.; Atzler, M.; Ugur, S.; Plett, C.; Rabe, A.; Kugler, C.; Rank, A.; Inngjerdingen, M.; Baudrexler, T.; Eiz-Vesper, B.; Schmid, C.; Schmetzer, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗